Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $794M | $1.22B | $1.52B | $2.39B | $4.32B | $6.06B | $5.93B |
| Revenue growth | — | 53.4% | 24.9% | 57.0% | 80.7% | 40.4% | -2.1% |
| Operating income | -$107M | -$56.7M | -$372M | -$105M | -$232M | -$292M | -$463M |
| Operating margin | -13.4% | -4.7% | -24.5% | -4.4% | -5.4% | -4.8% | -7.8% |
| Net income | -$283M | -$60.1M | -$406M | -$107M | -$263M | -$260M | -$391M |
| Net margin | -35.6% | -4.9% | -26.7% | -4.5% | -6.1% | -4.3% | -6.6% |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$104M | -$53.2M | -$148M | -$131M | -$156M | -$57.8M | -$106M |
| Capital expenditures | $2.89M | $1.77M | $6.56M | $15.4M | $15.8M | $13.3M | $13.2M |
| Free cash flow | -$107M | -$55.0M | -$155M | -$146M | -$172M | -$71.0M | -$119M |
| Share buybacks | — | $6.70M | — | — | $200M | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $139M | $107M | $1.04B | $465M | $108M | $188M | $174M |
| Total assets | — | $446M | $1.59B | $1.70B | $1.74B | $1.73B | $1.27B |
| Total liabilities | — | $422M | $495M | $657M | $1.08B | $1.26B | $1.14B |
| Long-term debt | — | $64.7M | $43.4M | $38.5M | $32.3M | $34.9M | $15.8M |
| Shareholders' equity | -$232M | -$285M | $1.09B | $1.04B | $661M | $471M | $127M |
| Retained earnings | — | -$551M | -$958M | -$1.06B | -$1.33B | -$1.59B | -$1.98B |
| Shares (wtd avg diluted) | — | 323M | 373M | 408M | 409M | 411M | 414M |
Every figure is extracted from agilon health, inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.